Biogen
Stock Forecast, Prediction & Price Target

Biogen (BIIB) stock Price Target by analysts

Last Year
Average Price Target

$242.33

Potential upside: 74.65%

Based on 9 analysts

Biogen price prediction

Strike.market

What is Biogen stock analysts` prediction?

Biogen stock forecast: Based on 9 Wall Street analysts` predicted price targets for Biogen in the last 3 months, the avarage price target is $242.33, with a high forecast of $NaN. The average price target represents a 74.65% change from the last price of $138.75.

Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.

Biogen stock Price Target by analysts

Full breakdown of analysts given Biogen price targets

Analyst name & company
Analyst win rate
Publish date
Price target
Price when posted
Source Historical targets
Michael Yee
Jefferies
33.33%
1/3
9 months ago $180 29.72% upside $157.78 StreetInsider
Previous targets (2)
Brian Skorney
Robert W. Baird
33.33%
1/3
10 months ago $300 116.21% upside $162.83 StreetInsider
Previous targets (2)
Jay Olson
Oppenheimer
0%
0/2
10 months ago $255 83.78% upside $181.18 StreetInsider
Previous targets (1)
Terence Flynn
Morgan Stanley
0%
0/2
10 months ago $204 47.02% upside $181.18 TheFly
Previous targets (1)
Salveen Richter
Goldman Sachs
33.33%
1/3
10 months ago $290 109.00% upside $181.18 StreetInsider
Previous targets (2)
Christopher Raymond
Raymond James
0%
0/2
10 months ago $315 127.02% upside $181.18 StreetInsider
Previous targets (1)
Evan Seigerman
BMO Capital
50%
1/2
11 months ago $230 65.76% upside $188.17 TheFly
Previous targets (1)
Ashwani Verma
UBS
0%
0/1
11 months ago $202 45.58% upside $188.74 TheFly
Previous targets (0)
Laura Chico
Wedbush
75%
3/4
12 months ago $205 47.74% upside $199.36 TheFly
Previous targets (3)
Brian Skorney
Robert W. Baird
33.33%
1/3
about 1 year ago $294 111.89% upside $212.7 StreetInsider
Previous targets (2)
Brian Abrahams
RBC Capital
33.33%
1/3
about 1 year ago $282 103.24% upside $214.16 StreetInsider
Previous targets (2)
Salveen Richter
Goldman Sachs
33.33%
1/3
about 1 year ago $342 146.48% upside $211.17 StreetInsider
Previous targets (2)
Christopher Raymond
Piper Sandler
33.33%
1/3
about 1 year ago $307 121.26% upside $211.17 StreetInsider
Previous targets (2)
Christopher Raymond
Piper Sandler
33.33%
1/3
about 1 year ago $313 125.58% upside $236.8 TheFly
Previous targets (2)
Terence Flynn
Morgan Stanley
0%
0/2
about 1 year ago $311 124.14% upside $232.75 TheFly
Previous targets (1)
George Farmer
Scotiabank
0%
0/1
about 1 year ago $275 98.19% upside $230.28 StreetInsider
Previous targets (0)
Evan David Seigerman
BMO Capital
0%
0/2
over 1 year ago $260 87.38% upside $220 StreetInsider
Previous targets (1)
Matthew Harrison
Morgan Stanley
33.33%
1/3
over 1 year ago $331 138.55% upside $224.48 StreetInsider
Previous targets (2)
Christopher Raymond
Raymond James
0%
0/2
over 1 year ago $335 141.44% upside $225.21 StreetInsider
Previous targets (1)
Paul Matteis
Stifel Nicolaus
0%
0/1
over 1 year ago $275 98.19% upside $225.21 StreetInsider
Previous targets (0)
Laura Chico
Wedbush
75%
3/4
over 1 year ago $215 54.95% upside $204.65 TheFly
Previous targets (3)
Brian Abrahams
RBC Capital
33.33%
1/3
over 1 year ago $317 128.46% upside $201.99 StreetInsider
Previous targets (2)
Andrew Fein
H.C. Wainwright
0%
0/1
over 1 year ago $300 116.21% upside $201.99 StreetInsider
Previous targets (0)
Jay Olson
Oppenheimer
0%
0/2
over 1 year ago $270 94.59% upside $190.52 StreetInsider
Previous targets (1)
Carter Gould
Barclays
66.67%
2/3
over 1 year ago $215 54.95% upside $206.38 TheFly
Previous targets (2)
Laura Chico
Wedbush
75%
3/4
about 2 years ago $269 93.87% upside $271.23 Benzinga
Previous targets (3)
Yatin Suneja
Guggenheim
50%
1/2
over 2 years ago $350 152.25% upside $311.11 Benzinga
Previous targets (1)
Unknown
Atlantic Equities
N/A
almost 3 years ago $295 112.61% upside $305.17 Benzinga
N/A
Unknown
Wedbush
N/A
almost 3 years ago $247 78.01% upside $302.84 Benzinga
N/A
Unknown
Barclays
N/A
almost 3 years ago $313 125.58% upside $291.41 Benzinga
N/A
Unknown
Jefferies
N/A
almost 3 years ago $350 152.25% upside $308.44 Benzinga
N/A
Unknown
Truist Financial
N/A
almost 3 years ago $350 152.25% upside $301.86 Benzinga
N/A
Unknown
Guggenheim
N/A
almost 3 years ago $270 94.59% upside $286.86 Benzinga
N/A
Unknown
J.P. Morgan
N/A
almost 3 years ago $275 98.19% upside $264.28 Benzinga
N/A
Unknown
Piper Sandler
N/A
almost 3 years ago $280 101.80% upside $197.79 Benzinga
N/A
Unknown
Wedbush
N/A
almost 3 years ago $217 56.39% upside $277.58 Benzinga
N/A
Salim Syed
Mizuho Securities
100%
2/2
almost 3 years ago $270 94.59% upside $197.79 StreetInsider
Previous targets (1)
Steve Chesney
Atlantic Equities
50%
1/2
almost 3 years ago $200 44.14% upside $271.17 Benzinga
Previous targets (1)
Matthew Harrison
Morgan Stanley
33.33%
1/3
almost 3 years ago $285 105.40% upside $271.14 Benzinga
Previous targets (2)
Ami Fadia
Needham
25%
1/4
almost 3 years ago $250 80.18% upside $271.17 Benzinga
Previous targets (3)
Unknown
Wells Fargo
N/A
almost 3 years ago $350 152.25% upside $270.29 Benzinga
N/A
Evan David Seigerman
BMO Capital
0%
0/2
almost 3 years ago $360 159.45% upside $197.79 StreetInsider
Previous targets (1)
Unknown
RBC Capital
N/A
almost 3 years ago $321 131.35% upside $275.88 Benzinga
N/A
Unknown
Truist Financial
N/A
almost 3 years ago $265 90.99% upside $195.92 Benzinga
N/A
Unknown
Stifel Nicolaus
N/A
almost 3 years ago $223 60.72% upside $215.38 Benzinga
N/A
Unknown
Truist Financial
N/A
about 3 years ago $270 94.59% upside $213.15 Benzinga
N/A
Unknown
Needham
N/A
about 3 years ago $250 80.18% upside $207.49 Benzinga
N/A
Unknown
Barclays
N/A
about 3 years ago $200 44.14% upside $212.95 Benzinga
N/A
Unknown
Oppenheimer
N/A
about 3 years ago $230 65.76% upside $216.68 Benzinga
N/A
Unknown
Barclays
N/A
over 3 years ago $210 51.35% upside $205.7 Benzinga
N/A

Biogen Financial Estimates

Biogen Revenue Estimates

Biogen EBITDA Estimates

Biogen Earnings per Share Estimates

Passed Analyst forecast
Metric 12/31/2021 12/31/2022 12/31/2023 12/31/2025 12/31/2026 12/31/2027 12/31/2028
Revenue
 
% change YoY
$10.98B
 
N/A
$10.17B
 
-7.36%
$9.83B
 
-3.32%
Avg: $9.56B
Low: $8.66B
High: $10.42B
avg. -2.76%
Avg: $9.88B
Low: $9.32B
High: $10.43B
avg. 3.39%
Avg: $10.35B
Low: $9.76B
High: $10.92B
avg. 4.69%
Avg: $10.76B
Low: $10.15B
High: $11.35B
avg. 3.94%
Net Income
 
% change YoY
$1.55B
 
N/A
$3.04B
 
95.80%
$1.16B
 
-61.89%
Avg: $2.21B
Low: $1.39B
High: $3.43B
avg. 90.93%
Avg: $2.57B
Low: $1.80B
High: $3.61B
avg. 16.20%
Avg: $3.20B
Low: $2.97B
High: $3.43B
avg. 24.51%
Avg: $3.49B
Low: $3.23B
High: $3.74B
avg. 8.99%
EBITDA
 
% change YoY
$3.65B
 
N/A
$2.68B
 
-26.54%
$2.37B
 
-11.50%
Avg: $3.33B
Low: $3.01B
High: $3.63B
avg. 40.15%
Avg: $3.44B
Low: $3.24B
High: $3.63B
avg. 3.39%
Avg: $3.60B
Low: $3.40B
High: $3.80B
avg. 4.69%
Avg: $3.74B
Low: $3.53B
High: $3.95B
avg. 3.94%
EPS
 
% change YoY
$10.44
 
N/A
$20.97
 
100.86%
$8.02
 
-61.75%
Avg: $14.82
Low: $9.6
High: $23.59
avg. 84.83%
Avg: $17.85
Low: $12.42
High: $24.84
avg. 20.38%
Avg: $22.03
Low: $20.41
High: $23.61
avg. 23.46%
Avg: $24.02
Low: $22.24
High: $25.74
avg. 8.99%
Operating Expenses
 
% change YoY
$6.06B
 
N/A
$4.99B
 
-17.65%
$6.00B
 
20.27%
Avg: $2.08B
Low: $1.89B
High: $2.27B
avg. -65.26%
Avg: $2.15B
Low: $2.03B
High: $2.27B
avg. 3.39%
Avg: $2.25B
Low: $2.12B
High: $2.38B
avg. 4.69%
Avg: $2.34B
Low: $2.21B
High: $2.47B
avg. 3.94%

FAQ

What is Biogen stock earnings growth forecast?

Wall Street analysts estimate the annual average earnings growth rate of 35.16% in 2025-2028.

We have gathered data from 24 analysts. Their low estimate is 1.39B, average is 2.21B and high is 3.43B.

What is Biogen stock revenue growth forecast?

Wall Street analysts forecast annual average revenue growth of 2.31% in 2025-2028.

We have gathered data from 29 analysts. Their low revenue estimate is $8.66B, average is $9.56B and high is $10.42B.

What is Biogen stock earnings per share growth forecast?

Wall Street analysts forecast annual average earnings growth of 34.42% in 2025-2028.

We have gathered data from 24 analysts. Their low earnings per share estimate is $9.6, average is $14.82 and high is $23.59.

What is the best performing analyst?

In the last twelve months 9 analysts have been covering Biogen stock. The most successful analyst is Michael Yee whose win rate is 33.33%. He has correctly predicted 1/3 price targets.